In a groundbreaking advance that could reshape the future of oncology, researchers at Shandong University in Qingdao, China, have successfully engineered a probiotic bacterium, Escherichia coli Nissle 1917 (EcN), to biosynthesize and deliver an FDA-approved anticancer drug directly to tumor cells. This innovative strategy, detailed in a recent publication in PLOS Biology, combines cutting-edge synthetic biology with targeted cancer therapy, establishing a new paradigm for the use of bacteria as living drug factories within the body.
Cancer remains one of the leading causes of death worldwide, with treatment modalities often hindered by tumor heterogeneity, systemic toxicity, and drug resistance. Against this challenging backdrop, scientists have long sought therapeutic vectors capable of localizing treatment within tumors while minimizing harm to healthy tissues. The probiotic strain EcN, naturally residing in the human gut and known for its safety profile, emerged as an ideal chassis for such interventions. Exploiting its inherent tumor-colonizing capability, the researchers genetically engineered EcN to produce Romidepsin (also known as FK228), a potent histone deacetylase inhibitor with established anticancer properties.
Romidepsin functions by modulating epigenetic regulation, thereby inducing cancer cell apoptosis and cell cycle arrest. Traditionally administered systemically with significant side effects, its localized biosynthesis within the tumor microenvironment by engineered EcN offers a highly targeted alternative. By integrating the biosynthetic pathway of Romidepsin into the bacterial genome, the modified EcN strain can autonomously synthesize and secrete this therapeutic compound upon colonizing tumor sites.
The team’s meticulous in vitro assays demonstrated robust production of Romidepsin by the engineered EcN under different culture conditions simulating the tumor microenvironment. Crucially, these bacteria maintained their viability and sustained drug synthesis without compromising their probiotic characteristics. Proceeding to in vivo studies, the researchers employed a murine model bearing orthotopic breast tumors. Upon intravenous administration, the engineered EcN selectively homed to the tumor tissue, effectively bypassing healthy organs and minimizing systemic exposure.
Within the tumor niche, the colonizing bacteria proliferated and delivered continuous localized doses of Romidepsin, leading to significant tumor growth inhibition compared to control groups receiving non-engineered bacteria or systemic chemotherapy. Histopathological analyses revealed increased tumor cell apoptosis and reduced proliferation markers, corroborating the dual action of EcN’s colonization and Romidepsin’s pharmacological effects.
This study’s implications extend beyond efficacy; it addresses critical safety concerns associated with bacteria-mediated therapies. The authors emphasize the need to develop strategies for controlled elimination of the therapeutic bacteria post-treatment to prevent potential adverse outcomes such as unintended infections or systemic dissemination. Future research directives include refining bacterial strains for optimized drug yield, engineering kill-switch mechanisms, and conducting rigorous toxicological assessments to transition from animal models to human clinical trials.
The innovative design exploits the symbiotic relationship between host and microbiota, highlighting the untapped potential of the human microbiome as a therapeutic platform. The dual-action mechanism of EcN combined with Romidepsin not only augments the therapeutic index but also leverages the natural tumor tropism of bacteria, minimizing off-target drug effects. This synergy exemplifies a novel biological engineering feat offering personalized, precision oncology solutions.
Experts in the field have hailed this proof-of-concept work as a significant stride toward biodegradable, self-sustaining cancer treatments that circumvent the pitfalls of conventional chemotherapy. The use of a broadly recognized probiotic bacterium also enhances translational feasibility, reducing regulatory barriers frequently posed by pathogenic bacterial vectors.
Despite these promising findings, the authors note the complexity of human tumor microenvironments and inter-patient variability as considerable challenges. Comprehensive studies elucidating EcN’s long-term colonization dynamics, immune interactions, and integration with existing therapeutic regimens are essential steps before clinical translation.
This pioneering investigation sets a precedent for designing multifunctional bacterial platforms that can be tailored to produce diverse small-molecule drugs, enabling an unprecedented modular approach to cancer therapy. By harnessing synthetic biology, researchers can now envision intricate microbial therapeutics capable of sensing, responding to, and remodeling tumor ecosystems in real time.
In conclusion, this study from Shandong University charts a bold new course in the field of bacteria-assisted tumor therapy, paving the way for revolutionary treatments that combine biological engineering with precision medicine. The potential to bio-manufacture potent anticancer agents within tumors themselves could revolutionize cancer care, decreasing systemic toxicity and improving patient outcomes.
With continued advancements, engineered probiotic strains like EcN may soon emerge as frontline weapons against cancer, signaling a paradigm shift that integrates microbiology, genetic engineering, and oncology into a cohesive therapeutic strategy. As the field eagerly anticipates human trials, this research represents a beacon of hope for millions battling malignancies worldwide.
Subject of Research: Animals
Article Title: Engineered romidepsin biosynthetic pathways in Escherichia coli Nissle 1917 improve the efficacy of bacteria-mediated cancer therapy
News Publication Date: March 17, 2026
Web References:
https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003657
http://dx.doi.org/10.1371/journal.pbio.3003657
References:
Ma C, Li G, Sun T, Tang X, Qiu T, Song J, et al. (2026) Engineered romidepsin biosynthetic pathways in Escherichia coli Nissle 1917 improve the efficacy of bacteria-mediated cancer therapy. PLoS Biol 24(3): e3003657.
Keywords:
Synthetic biology, Escherichia coli Nissle 1917, Romidepsin, FK228, cancer therapy, tumor-targeted delivery, bacterial cancer therapy, epigenetic modulation, histone deacetylase inhibitor, probiotic engineering, bacterial colonization, breast cancer model
Tags: Escherichia coli Nissle 1917 probiotic use in oncologygenetically engineered bacteria for cancer therapyhistone deacetylase inhibitors in cancerinnovative bacterial vectors for cancer drugslocalized anticancer drug productionovercoming tumor heterogeneity with bacterial therapyprobiotic bacteria as living drug factoriesreducing systemic toxicity in chemotherapyRomidepsin biosynthesis by engineered bacteriasynthetic biology in cancer treatmenttargeted drug delivery using bacteriatumor microenvironment targeted therapy
